These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26863533)

  • 1. Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines.
    Park J; Khloya P; Seo Y; Kumar S; Lee HK; Jeon DK; Jo S; Sharma PK; Namkung W
    PLoS One; 2016; 11(2):e0149131. PubMed ID: 26863533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.
    Namkung W; Park J; Seo Y; Verkman AS
    Mol Pharmacol; 2013 Sep; 84(3):384-92. PubMed ID: 23788656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating.
    Xu LN; Na WL; Liu X; Hou SG; Lin S; Yang H; Ma TH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):878-83. PubMed ID: 18430055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
    Wang F; Zeltwanger S; Hu S; Hwang TC
    J Physiol; 2000 May; 524 Pt 3(Pt 3):637-48. PubMed ID: 10790148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
    Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
    Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
    Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
    Liu X; Dawson DC
    Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
    Van Goor F; Straley KS; Cao D; González J; Hadida S; Hazlewood A; Joubran J; Knapp T; Makings LR; Miller M; Neuberger T; Olson E; Panchenko V; Rader J; Singh A; Stack JH; Tung R; Grootenhuis PD; Negulescu P
    Am J Physiol Lung Cell Mol Physiol; 2006 Jun; 290(6):L1117-30. PubMed ID: 16443646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
    Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional cystic fibrosis transmembrane conductance regulator tagged with an epitope of the vesicular stomatis virus glycoprotein can be addressed to the apical domain of polarized cells.
    Costa de Beauregard MA; Edelman A; Chesnoy-Marchais D; Tondelier D; Lapillonne A; El Marjou F; Robine S; Louvard D
    Eur J Cell Biol; 2000 Nov; 79(11):795-802. PubMed ID: 11139142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
    Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
    J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.
    Illek B; Zhang L; Lewis NC; Moss RB; Dong JY; Fischer H
    Am J Physiol; 1999 Oct; 277(4):C833-9. PubMed ID: 10516113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.